Peter W. White

Montreal, QC H4S1Z9, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Selective inhibition of CDK7 reveals high-confidence targets and new models for TFIIH function in transcription.

Selective inhibition of CDK7 reveals high-confidence targets and new models for TFIIH function in transcription.

Journal: Genes & development

Published: June 15, 2020

Structure-thermodynamics-relationships of hepatitis C viral NS3 protease inhibitors.

Structure-thermodynamics-relationships of hepatitis C viral NS3 protease inhibitors.

Journal: European journal of medicinal chemistry

Published: November 13, 2019

Integrated strategies for identifying leads that target the NS3 helicase of the hepatitis C virus.

Integrated strategies for identifying leads that target the NS3 helicase of the hepatitis C virus.

Journal: Journal of medicinal chemistry

Published: January 29, 2014

Human rhinovirus VPg uridylylation AlphaScreen for high-throughput screening.

Human rhinovirus VPg uridylylation AlphaScreen for high-throughput screening.

Journal: Journal of biomolecular screening

Published: July 02, 2013

Discovery of hepatitis C virus NS3-4A protease inhibitors with improved barrier to resistance and favorable liver distribution.

Discovery of hepatitis C virus NS3-4A protease inhibitors with improved barrier to resistance and favorable liver distribution.

Journal: Journal of medicinal chemistry

Published: March 20, 2013

Peptide backbone replacement of hepatitis C virus NS3 serine protease C-terminal cleavage product analogs: discovery of potent succinamide inhibitors.

Peptide backbone replacement of hepatitis C virus NS3 serine protease C-terminal cleavage product analogs: discovery of potent succinamide inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: March 08, 2013

Synthesis and optimization of a novel series of HCV NS3 protease inhibitors: 4-arylproline analogs.

Synthesis and optimization of a novel series of HCV NS3 protease inhibitors: 4-arylproline analogs.

Journal: Bioorganic & medicinal chemistry letters

Published: January 25, 2013

Molecular mechanism by which a potent hepatitis C virus NS3-NS4A protease inhibitor overcomes emergence of resistance.

Molecular mechanism by which a potent hepatitis C virus NS3-NS4A protease inhibitor overcomes emergence of resistance.

Journal: The Journal of biological chemistry

Published: December 29, 2012

Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target.

Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target.

Journal: Journal of virology

Published: August 17, 2012

The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic-pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in humans.

The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic-pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in humans.

Journal: Antimicrobial agents and chemotherapy

Published: August 08, 2012

In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335.

In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335.

Journal: Antimicrobial agents and chemotherapy

Published: October 26, 2011

Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor.

Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor.

Journal: Xenobiotica; the fate of foreign compounds in biological systems

Published: October 13, 2011

Showing 1-12 of 12

Last Updated: 09/26/2026